Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of two groups evaluating DFV890 in patients with myeloid diseases. The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, efficacy and recommended dose for single agent DFV890 in patients with lower risk (LR: very low, low or intermediate risk) myelodysplastic syndromes (LR MDS) and lower risk chronic myelomonocytic leukemia (LR CMML).
CDFV890G12101 is a medical study investigating a new agent called DFV890 in patients with certain types of blood cancer, known as myeloid disorders. These include low-risk myelodysplastic syndromes (MDS) and low-risk chronic myelomonocytic leukemia (CMML). Since this is an early phase, the main goal of the study is to evaluate the drug's safety, find out how well it is tolerated, and determine the recommended treatment dose. The study includes a dose-escalation part and a randomized part to optimize the dosing.
